TEMPR (Targeted Endogenous Mapping of Pharmacological Resistance): a CRISPR-based strategy to identify mutations in the MET kinase domain conferring resistance to Savolitinib
The European Laboratory Research & Innovation Group
Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
